ROCHESTER, Mich., Oct. 24, 2016 -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide point of care patient-care services, will hold a conference call on Monday, November 7, 2016 at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2016. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the presentation, followed by a question and answer period.
Date: Monday, November 7, 2016
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-877-627-6544
International dial-in number: 1-719-325-4874
Conference ID: 6212792
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 28, 2016, as well as available for replay via the Investors section of the OptimizeRx website at www.optimizerxcorp.com.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 6212792
About OptimizeRx Corp
OptimizeRx Corporation (OTCQB:OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.
The company’s core product replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and other EHRs to reach over 250,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go to www.optimizerxcorp.com.
Company Contact:
OptimizeRx
Doug Baker
[email protected]
248-651-6568 x807
Investor Relations Contact:
Liolios Group
Ron Both, Senior Managing Director
[email protected]
949-574-3860


Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



